EUCTR2004-000415-26-IT进行中（未招募）不适用
A DOUBLE-BLIND, DOSE-RANGE, PLACEBO CONTROLLED STUDYOF THE EFFECTS OF PST2238 VS. PLACEBO IN PATIENTSWITH STABLE, UNCOMPLICATED, ESSENTIAL HYPERTENSION.
SIGMA-TA0 个研究点目标入组 440 人开始时间: 2005年3月15日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 440
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
已完成
不适用
A DOUBLE-BLINDED, PLACEBO-CONTROLLED, SINGLE DOSE AND MULTIPLE-DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND PROOF OF CONCEPT OF DM-199 IN HEALTHY SUBJECTS AND PATIENTS WITH TYPE 2 DIABETES MELLITUSType2 Diabetes Mellitus: bloodglucose.10018424NL-OMON40545DiaMedica Inc.96
进行中（未招募）
不适用
A study on the safety, tolerability and the effect of DM-199 on the body, a new agent for the treatment of Diabetes Mellitus Type 2, after single- and multiple dosing in healthy volunteers and Diabetes Mellitus Type 2 patients.Diabetes Mellitus type 2MedDRA version: 16.1Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2013-000225-30-NLDiaMedica USA Inc.
进行中（未招募）
不适用
A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF AGI 003 IN THE TREATMENT OF NON-CONSTIPATION PREDOMINANT IRRITABLE BOWEL SYNDROME.EUCTR2004-002752-34-LTAGI Therapeutics Limited125
进行中（未招募）
1 期
A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF AGI 003 IN THE TREATMENT OF NON-CONSTIPATION PREDOMINANT IRRITABLE BOWEL SYNDROME.Irritable bowel syndrome (not constipation predominant).MedDRA version: 7.0Level: PTClassification code 10023003EUCTR2004-002752-34-GBAGI Therapeutics Limited125
已完成
不适用
A DOUBLE-BLIND, PLACEBO-CONTROLLED DOSE ESCALATION STUDY OF THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF A SUBCUTANEOUS DOSE OF SHK-186 IN HEALTHY SUBJECTSDisorder in which the body makes antibodies against bodys own proteins10003816NL-OMON36904Kineta One56